Unnamed: 0,title,date,stock,sentiment
389787.0,Dynavax Technologies shares are trading higher after company announced it completed the enrollment of its clinical trial evaluating HEPLISAV-B in patients undergoing Hemodialysis.,2020-06-09 08:21:00-04:00,DVAX,positive
389788.0,Dynavax Completes Enrollment Of Clinical Trial Evaluating HEPLISAV-B In Patients Undergoing Hemodialysis,2020-06-09 08:01:00-04:00,DVAX,neutral
389789.0,72 Biggest Movers From Yesterday,2020-06-03 05:11:00-04:00,DVAX,neutral
389790.0,50 Stocks Moving In Tuesday's Mid-Day Session,2020-06-02 12:21:00-04:00,DVAX,neutral
389791.0,"The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs",2020-06-02 07:45:00-04:00,DVAX,negative
389792.0,71 Biggest Movers From Yesterday,2020-06-02 04:39:00-04:00,DVAX,neutral
389793.0,48 Stocks Moving In Monday's Mid-Day Session,2020-06-01 12:34:00-04:00,DVAX,neutral
389794.0,72 Biggest Movers From Friday,2020-06-01 04:53:00-04:00,DVAX,neutral
389795.0,"Notable Insider Buys: Avis, Dynavax And Formula One",2020-05-30 17:12:00-04:00,DVAX,neutral
389796.0,50 Stocks Moving In Friday's Mid-Day Session,2020-05-29 12:15:00-04:00,DVAX,neutral
389797.0,Dynavax Shares Spike Higher As Traders Circulate Sky News Article On Effectiveness Of COVID-19 Vaccine; Shares Up 28%,2020-05-29 10:40:00-04:00,DVAX,positive
389798.0,Dynavax Technologies Option Alert: Jun 19 $6 Calls Sweep (17) near the Ask: 518 @ $0.901 vs 1964 OI; Ref=$5.9126,2020-05-29 10:33:00-04:00,DVAX,positive
389799.0,20 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-29 07:39:00-04:00,DVAX,neutral
389800.0,34 Stocks Moving in Friday's Pre-Market Session,2020-05-29 07:15:00-04:00,DVAX,neutral
389801.0,"Dynavax Technologies Corp Director Hack Buys 1,000,000 Shares @$5/Share",2020-05-28 17:16:00-04:00,DVAX,positive
389802.0,71 Biggest Movers From Friday,2020-05-26 04:30:00-04:00,DVAX,neutral
389803.0,46 Stocks Moving In Friday's Mid-Day Session,2020-05-22 12:45:00-04:00,DVAX,neutral
389804.0,Price Over Earnings Overview: Dynavax Technologies,2020-05-22 10:19:00-04:00,DVAX,neutral
389805.0,20 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-22 07:47:00-04:00,DVAX,neutral
389806.0,30 Stocks Moving in Friday's Pre-Market Session,2020-05-22 07:18:00-04:00,DVAX,neutral
389807.0,"The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray",2020-05-22 07:10:00-04:00,DVAX,neutral
389808.0,"7 Stocks To Watch For May 22, 2020",2020-05-22 04:45:00-04:00,DVAX,neutral
389809.0,8 Stocks Moving In Thursday's After-Hours Session,2020-05-21 16:53:00-04:00,DVAX,neutral
389810.0,Dynavax Technologies shares are trading lower the company announced a proposed public offering of common stock. No terms were disclosed.,2020-05-21 16:04:00-04:00,DVAX,negative
389811.0,Dynavax Technologies Announces Proposed Public Offering Of Common Stock; Terms Not Disclosed,2020-05-21 16:01:00-04:00,DVAX,neutral
389812.0,61 Biggest Movers From Yesterday,2020-05-20 04:50:00-04:00,DVAX,neutral
389813.0,44 Stocks Moving In Tuesday's Mid-Day Session,2020-05-19 12:48:00-04:00,DVAX,neutral
389814.0,Why Dynavax's Stock Is Trading Higher Today,2020-05-19 10:53:00-04:00,DVAX,neutral
389815.0,Mid-Morning Market Update: Markets Mixed; Walmart Beats Q1 Expectations,2020-05-19 10:28:00-04:00,DVAX,neutral
389816.0,Dynavax shares are trading higher after the company said it intends to provide an update on early-stage coronavirus vaccine candidate collaborations on May 19.,2020-05-19 09:05:00-04:00,DVAX,positive
389817.0,28 Stocks Moving in Tuesday's Pre-Market Session,2020-05-19 07:20:00-04:00,DVAX,neutral
389818.0,Dynavax 8-K Shows Co. Intends To Provide Update On Early-Stage Collaborations Related To Potential Development Of Coronavirus Vaccine Candidate On May 19,2020-05-18 17:07:00-04:00,DVAX,neutral
389819.0,Dynavax Technologies Q1 EPS $(0.150) Beats $(0.310) Estimate,2020-05-07 17:19:00-04:00,DVAX,neutral
389820.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,DVAX,negative
389821.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,DVAX,neutral
389822.0,Dynavax Reports Interim Analysis Of Ongoing Trial Of HEPLISAV-B In Patients Undergoing Hemodialysis,2020-04-28 16:12:00-04:00,DVAX,neutral
389823.0,Dynavax Technologies Option Alert: May 15 $4 Calls Sweep (6) near the Ask: 421 @ $0.351 vs 5984 OI; Earnings 5/7 After Close Ref=$4.08,2020-04-27 12:26:00-04:00,DVAX,positive
389824.0,Price Over Earnings Overview: Dynavax Technologies,2020-04-23 13:44:00-04:00,DVAX,neutral
389825.0,54 Stocks Moving In Thursday's Mid-Day Session,2020-04-23 12:24:00-04:00,DVAX,neutral
389826.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-04-23 07:31:00-04:00,DVAX,neutral
389827.0,38 Stocks Moving in Thursday's Pre-Market Session,2020-04-23 07:18:00-04:00,DVAX,neutral
389828.0,"A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Reports",2020-04-23 06:10:00-04:00,DVAX,neutral
389829.0,14 Stocks Moving In Wednesday's After-Hours Session,2020-04-22 17:17:00-04:00,DVAX,neutral
389830.0,Dynavax shares are trading higher after the company reported collaboration with Valneva to advance vaccine development for coronavirus.,2020-04-22 16:05:00-04:00,DVAX,positive
389831.0,"Valneva, Dynavax Report Collaboration To Advance Vaccine Development For Coronavirus",2020-04-22 16:01:00-04:00,DVAX,neutral
389832.0,How The COVID-19 Pandemic Could End,2020-04-20 16:33:00-04:00,DVAX,neutral
389833.0,Dynavax And Sinovac Announce Collaboration To Develop A Coronavirus Vaccine,2020-04-16 07:31:00-04:00,DVAX,neutral
389834.0,"The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO",2020-04-03 07:36:00-04:00,DVAX,neutral
389835.0,Dynavax Says It Will Withdraw Its FY20 Guidance For HEPLISAV-B Net Product Sales Due To Coronavirus Outbreak,2020-04-02 16:34:00-04:00,DVAX,neutral
389836.0,"Shares of several healthcare companies are trading higher, potentially rebounding from yesterday's weakness. NOTE: Equities appear mixed through the session following US jobs data.",2020-04-02 12:24:00-04:00,DVAX,negative
389837.0,Dynavax And CEPI Announce Collaboration To Support Global Effort To Develop A Vaccine For Coronavirus,2020-03-26 07:30:00-04:00,DVAX,positive
389838.0,Dynavax Reports Research Collaboration With Clover Biopharma To Evaluate Coronavirus Vaccine Candidate With CpG 1018 Adjuvant,2020-03-24 08:32:00-04:00,DVAX,neutral
389839.0,115 Biggest Movers From Yesterday,2020-03-19 06:22:00-04:00,DVAX,neutral
389840.0,96 Stocks Moving In Wednesday's Mid-Day Session,2020-03-18 12:39:00-04:00,DVAX,neutral
389841.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,DVAX,positive
389842.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,DVAX,negative
389843.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,DVAX,negative
389844.0,"H.C. Wainwright Reiterates Buy on Dynavax Technologies, Lowers Price Target to $12",2020-03-12 07:46:00-04:00,DVAX,negative
389845.0,Dynavax Technologies: Q4 Earnings Insights,2020-03-11 16:47:00-04:00,DVAX,neutral
389846.0,"Dynavax Technologies Q4 EPS $(0.44) Misses $(0.33) Estimate, Sales $10.6M Miss $11.96M Estimate",2020-03-11 16:12:00-04:00,DVAX,negative
389847.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,DVAX,positive
389848.0,"Earnings Scheduled For March 11, 2020",2020-03-11 04:28:00-04:00,DVAX,neutral
389849.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,DVAX,negative
389850.0,108 Biggest Movers From Yesterday,2020-03-03 04:57:00-05:00,DVAX,neutral
389851.0,55 Stocks Moving In Monday's Mid-Day Session,2020-03-02 11:52:00-05:00,DVAX,neutral
389852.0,Dynavax Technologies shares are trading higher after the company announced a collaboration with the University of Queensland for the development of a coronavirus vaccine.,2020-03-02 08:46:00-05:00,DVAX,positive
389853.0,Dynavax Announces Collaboration with the University of Queensland for Development of a Coronavirus Vaccine,2020-03-02 08:06:00-05:00,DVAX,neutral
389854.0,"Dynavax Technology shares are trading lower in sympathy with the overall market as concerns about the Wuhan coronavirus continue to grow, prompting travel bans in multiple Chinese cities.",2020-01-27 11:44:00-05:00,DVAX,positive
389855.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,DVAX,neutral
389856.0,116 Healthcare Stocks Moving In Wednesday's Session,2020-01-22 12:37:00-05:00,DVAX,neutral
389857.0,Dynavax Technologies shares are trading higher. The stock moved higher following unusual interest in next month's $7 call contract.,2020-01-16 15:51:00-05:00,DVAX,positive
389858.0,Dynavax Technologies Option Alert: Feb 21 $7 Calls Sweep (15) near the Ask: 535 @ $0.55 vs 231 OI; Earnings 2/25 After Close [est] Ref=$6.09,2020-01-16 12:51:00-05:00,DVAX,positive
389859.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,DVAX,positive
389860.0,Dynavax Appoints Ryan Spencer As Chief Executive Officer And To Board Of Directors,2019-12-16 16:16:00-05:00,DVAX,neutral
389861.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,DVAX,neutral
389862.0,Dynavax Technologies shares are trading higher. The company had a broke past the $6 resistance level.,2019-12-09 11:01:00-05:00,DVAX,negative
389863.0,"Dynavax Technologies Reports Partnership with Alberstons Pharmacies To Offer HEPLISAV-B Vaccine, No Terms Disclosed",2019-12-05 08:04:00-05:00,DVAX,negative
389864.0,Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed,2019-12-03 07:13:00-05:00,DVAX,neutral
389865.0,63 Biggest Movers From Yesterday,2019-11-21 04:49:00-05:00,DVAX,neutral
389866.0,Dynavax Technologies shares are trading lower in sympathy with weakness in the overall market after it was reported phase one of the US-China trade deal may not happen this year.,2019-11-20 14:36:00-05:00,DVAX,negative
389867.0,"Dynavax Technologies Q3 EPS $(0.49) Misses $(0.39) Estimate, Sales $10.2M Miss $10.31M Estimate",2019-11-06 16:57:00-05:00,DVAX,negative
389868.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,DVAX,positive
389869.0,Dynavax Technologies shares are trading higher in sympathy with the overall market on better-than-expected October jobs growth and optimism around the U.S.-China trade deal.,2019-11-01 15:52:00-04:00,DVAX,positive
389870.0,Dynavax Technologies shares are trading higher in sympathy with the overall market on optimism around the U.S.-China trade deal.,2019-10-25 11:50:00-04:00,DVAX,positive
389871.0,41 Biggest Movers From Yesterday,2019-10-23 05:09:00-04:00,DVAX,neutral
389872.0,Dynavax Technologies shares are trading higher. Not seeing any news to justify the price action.,2019-10-22 15:38:00-04:00,DVAX,positive
389873.0,"Benzinga's Top Upgrades, Downgrades For October 18, 2019",2019-10-18 09:53:00-04:00,DVAX,positive
389874.0,Dynavax Technologies shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a buy rating and a price target of $13 per share.,2019-10-18 09:20:00-04:00,DVAX,positive
389875.0,32 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-18 08:34:00-04:00,DVAX,neutral
389876.0,"HC Wainwright & Co. Initiates Coverage On Dynavax Technologies with Buy Rating, Announces $13 Price Target",2019-10-18 07:08:00-04:00,DVAX,neutral
389877.0,Shares of several healthcare companies are trading higher after multiple reports suggesting China is open to a partial trade deal surfaced. The reports renewed optimism in the upcoming U.S.-China trade talks.,2019-10-09 11:10:00-04:00,DVAX,positive
389878.0,50 Biggest Movers From Yesterday,2019-09-27 04:31:00-04:00,DVAX,neutral
389879.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,DVAX,neutral
389880.0,34 Stocks Moving In Thursday's Mid-Day Session,2019-09-26 12:29:00-04:00,DVAX,neutral
389881.0,Dynavax Technologies shares are trading lower despite no company-specific news. The stock has dropped approximately 12% in the last 5 days.,2019-09-26 10:37:00-04:00,DVAX,positive
389882.0,"Dynavax Technologies shares are trading lower despite no company-specific news. Stocks in the broader healthcare space have been volatile amid the 2020 Democratic primaries, in which healthcare policy has been a key issue.",2019-09-25 11:50:00-04:00,DVAX,positive
389883.0,Dynavax Technologies Option Alert: Jan 17 $6 Calls Sweep (3) near the Ask: 5670 @ $0.42 vs 2546 OI; Earnings 11/4 After Close [est] Ref=$4.425,2019-09-24 15:23:00-04:00,DVAX,positive
389884.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,DVAX,negative
389885.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Wednesday., September 04, 2019",2019-09-04 12:44:00-04:00,DVAX,positive
389886.0,66 Biggest Movers From Yesterday,2019-09-04 05:07:00-04:00,DVAX,neutral
389887.0,33 Stocks Moving in Friday's Pre-Market Session,2019-08-23 08:02:00-04:00,DVAX,neutral
389888.0,Dynavax Technologies shares are trading higher after a 13D filing showed Bain Capital holds a 9.99% stake in the company.,2019-08-22 16:28:00-04:00,DVAX,positive
389889.0,Dynavax 13D Shows Bain Capital Holds 9.99% Stake In Co.,2019-08-22 16:25:00-04:00,DVAX,neutral
389890.0,90 Biggest Movers From Friday,2019-08-12 05:49:00-04:00,DVAX,neutral
389891.0,Dynavax Technologies shares are trading higher after the stock broke the $3 and $3.25 resistance levels.,2019-08-09 15:01:00-04:00,DVAX,negative
389892.0,"Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock",2019-08-08 08:40:00-04:00,DVAX,neutral
389893.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,DVAX,neutral
389894.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,DVAX,neutral
389895.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,DVAX,neutral
389896.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,DVAX,neutral
389897.0,Stocks That Managed to Breach 52-Week Lows Friday,2019-07-26 15:45:00-04:00,DVAX,negative
389898.0,"The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint",2019-07-26 07:26:00-04:00,DVAX,neutral
389899.0,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",2019-07-25 07:21:00-04:00,DVAX,negative
389900.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-07-24 13:57:00-04:00,DVAX,neutral
389901.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,DVAX,neutral
389902.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,DVAX,neutral
389903.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,DVAX,negative
389904.0,"Benzinga's Top Upgrades, Downgrades For July 11, 2019",2019-07-11 09:23:00-04:00,DVAX,positive
389905.0,Dynavax Technologies shares are trading higher after Cantor Fitzgerald upgraded the company's stock from Neutral to Overweight.,2019-07-11 09:17:00-04:00,DVAX,negative
389906.0,Cantor Fitzgerald Upgrades Dynavax Technologies to Overweight,2019-07-11 06:34:00-04:00,DVAX,negative
389907.0,Dynavax Technologies shares are trading higher after Cantor Fitzgerald moved the stock from Not Rated to Overweight and announced a $20 price target.,2019-07-10 16:46:00-04:00,DVAX,positive
389908.0,"Cantor Fitzgerald Moves Dynavax From Not Rated To Overweight, Announces $20 PT",2019-07-10 16:41:00-04:00,DVAX,positive
389909.0,33 Biggest Movers From Friday,2019-07-08 05:44:00-04:00,DVAX,neutral
389910.0,24 Stocks Moving In Friday's Mid-Day Session,2019-07-05 12:41:00-04:00,DVAX,neutral
389911.0,48 Biggest Movers From Wednesday,2019-07-05 05:08:00-04:00,DVAX,neutral
389912.0,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix",2019-06-07 07:24:00-04:00,DVAX,positive
389913.0,"The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer",2019-06-04 07:45:00-04:00,DVAX,negative
389914.0,Dynavax Highlights Presentation Of Results Showing 76% OVerall Response Rate In Advanced Melanoma Patients With SD-101 In Combination With KEYTRUDA,2019-06-03 14:18:00-04:00,DVAX,positive
389915.0,Dynavax Sat. Announced Presentation Of Phase 2 Data on SD-101 in Combination with KEYTRUDA®for Patients with Head and Neck Squamous Cell Carcinoma at ASCO,2019-06-03 09:54:00-04:00,DVAX,neutral
389916.0,Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA for Patients with Head and Neck Squamous Cell Carcinoma at #ASCO19; Announces Overall Response Rate of 24%,2019-06-01 15:27:00-04:00,DVAX,neutral
389917.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,DVAX,positive
389918.0,50 Biggest Movers From Friday,2019-05-28 05:01:00-04:00,DVAX,neutral
389919.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,DVAX,neutral
389920.0,Dynavax Technologies shares are trading lower on continued momentum from yesterday's news of the company restructuring and exploration of strategic alternatives for its Immuno-Oncology programs.,2019-05-24 15:01:00-04:00,DVAX,positive
389921.0,"The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice",2019-05-24 07:44:00-04:00,DVAX,neutral
389922.0,Dynavax shares trading lower following news of a restructuring and exploration of strategic alternatives for its Immuno-Oncology programs.,2019-05-23 17:23:00-04:00,DVAX,positive
389923.0,"Dynavax Shares Resume Trade, Down 7%",2019-05-23 17:22:00-04:00,DVAX,positive
389924.0,Dynavax Shares To Resume Trade At 5:15 p.m. EDT,2019-05-23 16:49:00-04:00,DVAX,positive
389925.0,Dynavax Says CEO Eddie Gray To Retire,2019-05-23 16:48:00-04:00,DVAX,neutral
389926.0,"UPDATE: Dynavax Says Will Reduce Co. Workforce, Operations To Focus Resources On HEPLISAV-B Commercialization",2019-05-23 16:47:00-04:00,DVAX,neutral
389927.0,Dynavax To Restructure to Prioritize Its Vaccine Unit By Focusing Co.'s First Commercial Product HEPLISAV-B,2019-05-23 16:47:00-04:00,DVAX,neutral
389928.0,Dynavax Reports Co. Will Explore Strategic Alternatives For Its Immuno-Oncology Programs,2019-05-23 16:46:00-04:00,DVAX,neutral
389929.0,Dynavax Shares Halted News Pending,2019-05-23 16:43:00-04:00,DVAX,positive
389930.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,DVAX,negative
389931.0,82 Biggest Movers From Yesterday,2019-05-10 06:27:00-04:00,DVAX,neutral
389932.0,"Dynavax Technologies Q1 EPS $(0.62) Beats $(0.65) Estimate, Sales $5.6M Inline",2019-05-08 16:49:00-04:00,DVAX,neutral
389933.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,DVAX,negative
389934.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,DVAX,neutral
389935.0,Dynavax Reports First Patient Enrolled In Study Of HEPLISAV-B In Adults With End-Stage Renal Disease,2019-05-02 18:37:00-04:00,DVAX,neutral
389936.0,"Dynavax Announces First Patient Enrolled In Study Of HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] In Adults With End-Stage Renal Disease",2019-05-02 18:36:00-04:00,DVAX,neutral
389937.0,"The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio",2019-04-18 07:42:00-04:00,DVAX,neutral
389938.0,Dynavax Highlights Presentation Of Phase 1b Data On Inhaled DV281 TLR9 Agonist At 2019 AACR Annual Meeting,2019-04-02 13:00:00-04:00,DVAX,neutral
389939.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,DVAX,neutral
389940.0,UPDATE: Dynavax Says 'Combination of SD-101 with domatinostat showed better results than combinations of SD-101 with competing HDAC inhibitors',2019-04-01 13:02:00-04:00,DVAX,positive
389941.0,Dynavax Reports Combo Of 4SC's 202 With Co.'s SD-101 'induced a systemic anti-tumoral immune response in tumor mouse models',2019-04-01 13:02:00-04:00,DVAX,negative
389942.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,DVAX,neutral
389943.0,Dynavax Reports EMA Accepted Marketing Authorization Application For HEPLISAV-B For Prevention Of Hep B In Adults,2019-03-28 16:32:00-04:00,DVAX,positive
389944.0,"The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering",2019-03-21 07:51:00-04:00,DVAX,negative
389945.0,"The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed",2019-03-19 07:40:00-04:00,DVAX,neutral
389946.0,Dynavax Reports Exercised Option for $75M In Non-Dilutive Debt,2019-03-18 16:26:00-04:00,DVAX,negative
389947.0,"Dynavax Technologies Q4 EPS $(0.64) Misses $(0.61) Estimate, Sales $5.318M Beat $3.43M Estimate",2019-02-26 16:59:00-05:00,DVAX,negative
389948.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,DVAX,positive
389949.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,DVAX,neutral
389950.0,55 Biggest Movers From Yesterday,2019-01-16 05:12:00-05:00,DVAX,neutral
389951.0,"Jim Cramer Shares His Thoughts On Alibaba, Dynavax, Starbucks And More",2019-01-15 07:22:00-05:00,DVAX,positive
389952.0,Dynavax Technologies Reports Partnership With Wal-Mart's Sam's Club To Bring HEPLISAV-B Into Sam's Club Retail Pharmacies In US,2019-01-08 09:02:00-05:00,DVAX,neutral
389953.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,DVAX,neutral
389954.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,DVAX,neutral
389955.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,DVAX,neutral
389956.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,DVAX,positive
389957.0,Dynavax Technologies Informed By Collaborator AstraZeneca That Initial High-Level Results From Phase 2a Study Indicate AZD1419 Did Not Meet Primary Endpoint; AstraZeneca To Review Will Data Before Deciding Next Steps,2018-11-29 17:08:00-05:00,DVAX,neutral
389958.0,"Dynavax Technologies Q3 EPS $(0.65) Misses $(0.57) Estimate, Sales $1.461M Miss $3.75M Estimate",2018-11-05 16:39:00-05:00,DVAX,negative
389959.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,DVAX,neutral
389960.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,DVAX,negative
389961.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,DVAX,negative
389962.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,DVAX,negative
389963.0,56 Biggest Movers From Yesterday,2018-10-24 05:53:00-04:00,DVAX,neutral
389964.0,Dynavax shares are trading up 9.3%; The stock continues to rally after company on Monday announced positive clinical data for its advanced melanoma therapy.,2018-10-23 15:31:00-04:00,DVAX,positive
389965.0,58 Biggest Movers From Yesterday,2018-10-23 05:09:00-04:00,DVAX,neutral
389966.0,"10 Hottest Stocks From October 22, 2018",2018-10-22 16:55:00-04:00,DVAX,neutral
389967.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Oct. 22, 2018",2018-10-22 16:20:00-04:00,DVAX,positive
389968.0,11 Stocks That Moved From ESMO 2018,2018-10-22 13:39:00-04:00,DVAX,neutral
389969.0,45 Stocks Moving In Monday's Mid-Day Session,2018-10-22 12:39:00-04:00,DVAX,neutral
389970.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Mon., Oct. 22, 2018",2018-10-22 10:23:00-04:00,DVAX,positive
389971.0,Dynavax shares are trading higher after the company announced strong data for a melanoma treatment.,2018-10-22 09:09:00-04:00,DVAX,positive
389972.0,30 Stocks Moving In Monday's Pre-Market Session,2018-10-22 08:05:00-04:00,DVAX,neutral
389973.0,Dynavax Announces SD-101 in Combination with Merck's KEYTRUDA Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at ESMO 2018,2018-10-20 16:28:00-04:00,DVAX,positive
389974.0,Dynavax Technologies and Quantum Leap Healthcare Announce a New Study for the Treatment of Locally Advanced Breast Cancer,2018-10-15 06:09:00-04:00,DVAX,negative
389975.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",2018-10-14 13:21:00-04:00,DVAX,neutral
389976.0,13G From HealthCor Management Shows Raised Stake In Dynavax Technologies From ~2.5M Shares To 3.45M Shares,2018-10-11 16:08:00-04:00,DVAX,positive
389977.0,Dynavax To Present New Data For SD-101 in Combination With KEYTRUDA At The European Society For Medical Oncology 2018 Congress October 19-23,2018-10-09 06:02:00-04:00,DVAX,neutral
389978.0,"Stocks Which Set New 52-Week Low Friday, October 5th",2018-10-08 09:27:00-04:00,DVAX,negative
389979.0,"Stocks Which Set New 52-Week Low Yesterday, October 2nd",2018-10-03 13:01:00-04:00,DVAX,negative
389980.0,"Stocks Which Set New 52-Week Low Yesterday, September 19th",2018-09-20 11:26:00-04:00,DVAX,negative
389981.0,"Stocks Which Set New 52-Week Low Friday, September 14",2018-09-17 09:30:00-04:00,DVAX,negative
389982.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,DVAX,negative
389983.0,"Stocks Which Set New 52-Week Low Yesterday, September 12th",2018-09-13 10:19:00-04:00,DVAX,negative
389984.0,"The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx",2018-09-13 08:42:00-04:00,DVAX,neutral
389985.0,"Dynavax Announces Publication of Two Papers In Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101",2018-08-28 06:33:00-04:00,DVAX,neutral
389986.0,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows",2018-08-21 08:40:00-04:00,DVAX,positive
389987.0,"Stocks Which Set New 52-Week Low Yesterday, August 16th",2018-08-17 10:40:00-04:00,DVAX,negative
389988.0,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns",2018-08-17 08:15:00-04:00,DVAX,negative
389989.0,"Dynavax Technologies Q2 EPS $(0.63), Inline, Sales $1.25M Miss $1.62M Estimate",2018-08-06 16:09:00-04:00,DVAX,negative
389990.0,Dynavax Technologies Option Alert: Jan 18 $14 Calls Sweep (9) near the Bid: 657 @ $2.7 vs 1 OI; Earnings 8/1 Before Open [est] Ref=$14.225,2018-07-26 13:17:00-04:00,DVAX,positive
389991.0,"Jim Cramer Weighs In On Barrick Gold, Childrens Place And More",2018-07-17 07:31:00-04:00,DVAX,neutral
389992.0,UPDATE: Dynavax Says 'This analysis showed that HEPLISAV-B resulted in a 90.0% seroprotection rate compared to a 65.1% seroprotection rate from Engerix-B',2018-06-25 12:08:00-04:00,DVAX,neutral
389993.0,"Dynavax Technologies Reports Results Of Post Hoc Analysis Of Data From HBV 23: Showed Was Well-Tolerated, Induced Higher Rates Of Seroprotection Than Engerix-B",2018-06-25 12:07:00-04:00,DVAX,neutral
389994.0,Dynavax Reports Phase 1b/2 Trial of SD-101 Overall Response Rate (ORR) of 70% and 6-month Progression Free Survival (PFS) rate of 76% in Patients Naïve to Anti-PD-1 Treatment who Received the ≤ 2mg Dose of SD-101,2018-06-04 14:22:00-04:00,DVAX,positive
389995.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,DVAX,negative
389996.0,48 Biggest Movers From Yesterday,2018-05-18 04:54:00-04:00,DVAX,neutral
389997.0,"Dynavax Shares Down 14.5%; Co. Reported SD-101 Overall Response Rate Of 60%, Excluding 5 Patients Who Dropped Out; STAT News' Adam Feuerstein, The Top Pharma/Biotech Reporter, Noted When The 5 Patients Were Added Back To Trial, Response Rate Was 50%",2018-05-17 14:06:00-04:00,DVAX,positive
389998.0,32 Stocks Moving In Thursday's Mid-Day Session,2018-05-17 12:34:00-04:00,DVAX,neutral
389999.0,'$DVAX reporting SD-101 ORR 60% but that's excluding 5 patients who dropped out early. Add those patients back (which you should do) and ORR drops to 50%. Meh. #ASCO18',2018-05-17 07:20:00-04:00,DVAX,negative
390000.0,55 Biggest Movers From Yesterday,2018-05-11 04:39:00-04:00,DVAX,neutral
390001.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-05-10 12:43:00-04:00,DVAX,neutral
390002.0,JPMorgan Sees Entry Point In Dynavax Ahead Of June Oncology Conference,2018-05-10 12:18:00-04:00,DVAX,neutral
390003.0,Dynavax Shares Up 17.0% After JP Morgan Earlier Upgraded To Overweight,2018-05-10 12:16:00-04:00,DVAX,positive
390004.0,JP Morgan Upgrades Dynavax Technologies to Overweight,2018-05-10 08:59:00-04:00,DVAX,neutral
390005.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-05-10 08:08:00-04:00,DVAX,neutral
390006.0,"Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway",2018-05-09 07:48:00-04:00,DVAX,neutral
390007.0,"Dynavax Technologies Q1 EPS $(0.63) Misses $(0.49) Estimate, Sales $165K Miss $660K Estimate",2018-05-08 16:13:00-04:00,DVAX,negative
390008.0,Dynavax Option Alert: May 18 $17 Puts Sweep (2) at the Ask: 500 @ $0.75 vs 3 OI; Earnings 5/7 Before Open [est] Ref=$17.95,2018-04-20 14:26:00-04:00,DVAX,positive
390009.0,11 Stocks Moving In Monday's After-Hours Session,2018-04-16 17:28:00-04:00,DVAX,neutral
390010.0,"Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA, Results Showed 'Encouraging Response Rates'",2018-04-16 14:11:00-04:00,DVAX,positive
390011.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-16 08:41:00-04:00,DVAX,neutral
390012.0,23 Stocks Moving In Monday's Pre-Market Session,2018-04-16 08:10:00-04:00,DVAX,neutral
390013.0,"Hearing JP Morgan Commenting On Dynavax: Given ~30+% Response Rate Shown In Initial 1b/2 Trial Of SD-101 + Pembro Is Confirmed In Full Presentation, Stock Should Be Up ~35+% From Current Levels In Early Trading",2018-04-16 07:30:00-04:00,DVAX,positive
390014.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-13 11:38:00-04:00,DVAX,neutral
390015.0,"Dynavax Reports Q4 EPS $(0.45) vs $(0.33) Est., Sales $21K vs $4.11M Est.",2018-03-08 06:31:00-05:00,DVAX,neutral
390016.0,Dynavax Clears Heplisav-B Hurdle With CDC Recommendation,2018-02-21 10:32:00-05:00,DVAX,positive
390017.0,Dynavax Reports HEPLISAV-B Recommended By CDC Panel For Prevention Of Hep B In Adults,2018-02-21 09:37:00-05:00,DVAX,positive
390018.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-19 10:50:00-05:00,DVAX,neutral
390019.0,"Benzinga's Top Upgrades, Downgrades For February 14, 2018",2018-02-14 09:32:00-05:00,DVAX,positive
390020.0,JP Morgan Downgrades Dynavax Technologies to Neutral,2018-02-14 08:18:00-05:00,DVAX,positive
390021.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-01-24 08:14:00-05:00,DVAX,neutral
390022.0,"JP Morgan Healthcare Conference Concludes Today, Presenters Include: CymaBay, Orthofix, Analogic, Achaogen, Immunomedics, and Dynavax",2018-01-11 09:07:00-05:00,DVAX,positive
390023.0,"Cowen Says They Believe Dynavax Is Undervalued For Heplisav, Continues To Expect Heplisav To Become Market Leading HBV Vaccine Following Launch Of Heplisav-B In U.S. With Pricing Disclosed",2018-01-08 11:41:00-05:00,DVAX,neutral
390024.0,Dynavax Option Alert: Feb 16 $17 Puts Sweep (8) at the Ask: 718 @ $1.25 vs 378 OI; Earnings 3/12 Before Open [est] Ref=$17.8,2018-01-08 10:50:00-05:00,DVAX,positive
390025.0,Dynavax Announces HEPLISAV-B Now Available in US for the Prevention of Hepatitis B in Adults,2018-01-08 06:43:00-05:00,DVAX,neutral
390026.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,DVAX,neutral
390027.0,FDA Decisions In November: The Month In Review,2017-12-01 14:05:00-05:00,DVAX,neutral
390028.0,Dynavax Option Alert: Dec 15 $20 Calls Sweep (2) at the Ask: 1000 @ $1.2 vs 1272 OI; Ref=$20.1,2017-11-29 10:07:00-05:00,DVAX,positive
390029.0,"VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO",2017-11-15 13:04:00-05:00,DVAX,positive
390030.0,Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate,2017-11-15 07:36:00-05:00,DVAX,positive
390031.0,Dynavax Under Selling Pressure,2017-11-13 13:34:00-05:00,DVAX,negative
390032.0,35 Stocks Moving In Friday's Mid-Day Session,2017-11-10 12:41:00-05:00,DVAX,neutral
390033.0,"At Long Last, Dynavax Wins FDA Approval For Heplisav",2017-11-10 08:44:00-05:00,DVAX,positive
390034.0,31 Stocks Moving In Friday's Pre-Market Session,2017-11-10 08:19:00-05:00,DVAX,neutral
390035.0,"7 Stocks To Watch For November 10, 2017",2017-11-10 05:09:00-05:00,DVAX,neutral
390036.0,10 Stocks Moving In Thursday's After-Hours Session,2017-11-09 17:04:00-05:00,DVAX,neutral
390037.0,Dynavax Shares Spiking Higher As FDA Approves HEPLISAV-B For Prevention Of Hep B In Adults,2017-11-09 16:48:00-05:00,DVAX,positive
390038.0,Dynavax Awaits FDA Verdict On Hepatitis B Vaccine,2017-11-08 15:04:00-05:00,DVAX,positive
390039.0,"Jim Cramer Shares His Thoughts On Dynavax, Whiting Petroleum And Lumentum",2017-11-08 07:37:00-05:00,DVAX,positive
390040.0,"The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket",2017-11-06 10:48:00-05:00,DVAX,neutral
390041.0,"Dynavax Q3 EPS $(0.38) vs $90.47) Est., Sales $53K vs $220K Est.",2017-11-03 06:31:00-04:00,DVAX,neutral
390042.0,Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon,2017-10-31 07:52:00-04:00,DVAX,neutral
390043.0,Dynavax Shares Down 7.17% Today Following Reports Of Conference Call With JP Morgan Monday,2017-10-17 12:34:00-04:00,DVAX,positive
390044.0,Dynavax Shares Down 6.62% On Heavy Volume; Earlier The Fly Reported The Co. To Hold Conf. Call With JP Morgan At 1pm ET,2017-10-16 13:11:00-04:00,DVAX,positive
390045.0,4 Breakout Biotech And Tech Charts To Watch,2017-10-05 12:33:00-04:00,DVAX,neutral
390046.0,Dynavax Shares Up 7% Premarket Amid Report 'Dynavax explores options for Hepatitis B drug',2017-10-02 08:43:00-04:00,DVAX,positive
390047.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-02 08:11:00-04:00,DVAX,neutral
390048.0,28 Stocks Moving In Wednesday's Pre-Market Session,2017-09-20 08:08:00-04:00,DVAX,neutral
390049.0,"Benzinga's Top Upgrades, Downgrades For September 15, 2017",2017-09-15 09:29:00-04:00,DVAX,positive
390050.0,"Cantor Fitzgerald Initiates Coverage On Dynavax Technologies with Overweight Rating, Announces $24.00 Price Target",2017-09-15 08:07:00-04:00,DVAX,negative
390051.0,Dynavax: Buy On Weakness Ahead Of November's PDUFA Date,2017-09-13 09:43:00-04:00,DVAX,negative
390052.0,Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts,2017-09-01 14:03:00-04:00,DVAX,neutral
390053.0,20 Stocks Moving In Friday's Pre-Market Session,2017-09-01 08:02:00-04:00,DVAX,neutral
390054.0,Dynavax Announces 5.75M Share Offering Common Stock,2017-08-15 16:02:00-04:00,DVAX,positive
390055.0,20 Stocks Moving In Monday's Pre-Market Session,2017-08-14 08:09:00-04:00,DVAX,neutral
390056.0,25 Biggest Mid-Day Losers For Thursday,2017-08-10 13:03:00-04:00,DVAX,negative
390057.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-08-10 08:04:00-04:00,DVAX,neutral
390058.0,Dynavax Reports Offering Of $125M In Common Shares,2017-08-08 16:25:00-04:00,DVAX,positive
390059.0,28 Stocks Moving In Friday's Pre-Market Session,2017-08-04 08:30:00-04:00,DVAX,neutral
390060.0,Dynavax Says FDA Has Requested More Info About Proposed Post Market Study For HEPLISAV-B,2017-08-03 16:01:00-04:00,DVAX,neutral
390061.0,"Jim Cramer Gives His Opinion On Akamai Technologies, Chevron And Others",2017-08-03 09:29:00-04:00,DVAX,neutral
390062.0,"Dynavax Reports Q2 EPS $(0.41) vs $(0.45) Est., Sales $105K",2017-08-02 06:02:00-04:00,DVAX,neutral
390063.0,Key FDA Events To Watch Out For In August 2017,2017-08-01 12:39:00-04:00,DVAX,neutral
390064.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,DVAX,neutral
390065.0,Dynavax Now Has A De-Risked Asset With Long-Term Potential,2017-07-31 15:42:00-04:00,DVAX,positive
390066.0,Mid-Afternoon Market Update: CDI Gains On Acquisition News; Hertz Global Shares Slide,2017-07-31 14:39:00-04:00,DVAX,positive
390067.0,15 Biggest Mid-Day Gainers For Monday,2017-07-31 12:30:00-04:00,DVAX,neutral
390068.0,Mid-Day Market Update: Dynavax Jumps After FDA Approval For Hepatitis B Vaccine; Navigant Shares Drop,2017-07-31 12:19:00-04:00,DVAX,positive
390069.0,Dynavax Up 70% After FDA Vote For Hepatitis B Vaccine,2017-07-31 10:58:00-04:00,DVAX,neutral
390070.0,Mid-Morning Market Update: Markets Mostly Higher; Discovery Communications To Acquire Scripps Networks Interactive,2017-07-31 10:21:00-04:00,DVAX,neutral
390071.0,"Benzinga's Top Upgrades, Downgrades For July 31, 2017",2017-07-31 09:30:00-04:00,DVAX,positive
390072.0,"Companies Holding Shareholder Meetings Today Include: CorMedix, Dynavax, Exeter Resource, magicJack, National Grid, Osisko Gold Royalties, and Proteon Therapeutics",2017-07-31 09:09:00-04:00,DVAX,neutral
390073.0,"Dynavax Shares Up 92% Pre-Market Following Favorable FDA Vote For HEPLISAV-B On Friday, RBC Capital Upgrade",2017-07-31 08:49:00-04:00,DVAX,positive
390074.0,22 Stocks Moving In Monday's Pre-Market Session,2017-07-31 08:39:00-04:00,DVAX,neutral
390075.0,A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Economic Data,2017-07-31 07:53:00-04:00,DVAX,neutral
390076.0,RBC Capital Upgrades Dynavax Technologies to Outperform,2017-07-31 07:48:00-04:00,DVAX,neutral
390077.0,"8 Stocks To Watch For July 31, 2017",2017-07-31 05:10:00-04:00,DVAX,neutral
390078.0,"Dynavax Shares Resume Trade, Up 75%",2017-07-28 17:15:00-04:00,DVAX,positive
390079.0,Dynavax Gets 12-1 FDA Vote For Hepatitis B Vaccine,2017-07-28 16:59:00-04:00,DVAX,neutral
390080.0,Dynavax Press Release Confirms FDA Panel Voted In Favor Of HEPLISAV-B,2017-07-28 16:41:00-04:00,DVAX,positive
390081.0,FDA Advisory Panel Votes 11 to 1 in Support of FDA Approval of Dynavax's Hepatitis B Vaccine,2017-07-28 15:04:00-04:00,DVAX,positive
390082.0,Dynavax Technologies Shares Halted News Pending,2017-07-28 07:07:00-04:00,DVAX,positive
390083.0,Dynavax Shares Sell off to Low of $9 Following Release of FDA Briefing Documents Reporting Deaths,2017-07-26 08:46:00-04:00,DVAX,neutral
390084.0,FDA Releases Dynavax Briefing Document,2017-07-26 08:22:00-04:00,DVAX,neutral
390085.0,Dyanvax Spikes to High of $13.00,2017-07-26 08:20:00-04:00,DVAX,neutral
390086.0,20 Stocks Moving In Wednesday's Pre-Market Session,2017-07-05 08:15:00-04:00,DVAX,neutral
390087.0,Mid-Morning Market Update: Markets Mostly Flat; Accenture Posts In-Line Q3 Earnings,2017-06-22 10:09:00-04:00,DVAX,neutral
390088.0,Dynavax Shares Tick Higher Off Session Lows As Hearing Agora Newsletter Making Positive Comments,2017-06-21 12:50:00-04:00,DVAX,positive
390090.0,Mid-Day Market Update: Crude Oil Down Over 3%; Lipocine Shares Spike Higher,2017-06-20 12:01:00-04:00,DVAX,negative
390091.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-06-07 08:05:00-04:00,DVAX,neutral
390092.0,Dynavax +5.7% Premarket @ $7.40; Point72 Reported 5.2% Passive Stake in 13G on Tuesday,2017-06-07 06:11:00-04:00,DVAX,positive
390093.0,13G Filing from Point72 on Dynavax Shows New 5.2% Stake,2017-06-06 16:23:00-04:00,DVAX,neutral
390094.0,Mid-Afternoon Market Update: Loxo Oncology Surges After Positive Results From Larotrectinib Trial; Microbot Medical Shares Plunge,2017-06-05 15:16:00-04:00,DVAX,positive
390095.0,12 Biggest Mid-Day Gainers For Monday,2017-06-05 12:35:00-04:00,DVAX,neutral
390096.0,Mid-Day Market Update: Crude Oil Down 1%; Forestar Shares Spike Higher,2017-06-05 12:03:00-04:00,DVAX,negative
390097.0,25 Stocks Moving In Monday's Pre-Market Session,2017-06-05 08:07:00-04:00,DVAX,neutral
390098.0,Dynavax +21% Premarket @$7.15; Co on Friday Presented Updated Data for SD-101 in Combination with KEYTRUDA,2017-06-05 07:52:00-04:00,DVAX,neutral
390099.0,Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy,2017-06-02 16:20:00-04:00,DVAX,negative
390100.0,"Dynavax Q1 EPS $(0.60) vs $(0.51) Est, Sales $148K vs $1.53M Est",2017-05-08 06:06:00-04:00,DVAX,neutral
390101.0,Watch These 8 Huge Call Purchases In Monday Trade,2017-04-10 06:52:00-04:00,DVAX,positive
390102.0,Benzinga's Option Alert Recap From April 7,2017-04-07 16:30:00-04:00,DVAX,positive
390103.0,Watch These 8 Huge Call Purchases In Thursday Trade,2017-04-06 04:08:00-04:00,DVAX,positive
390104.0,Benzinga's Option Alert Recap From April 5,2017-04-05 16:35:00-04:00,DVAX,positive
390105.0,Option Alert: Dynavax  Aug 7.0 Calls: 620 @  ASK  $1.90: 700 traded vs 0 OI:  Earnings 5/9 Before Open [est]  $5.47 Ref,2017-04-05 10:20:00-04:00,DVAX,positive
390106.0,22 Stocks Moving In Monday's Pre-Market Session,2017-04-03 08:35:00-04:00,DVAX,neutral
390107.0,Dynavax Says PDUFA Date for HEPLISAV-B to Remain Unchanged,2017-04-03 06:02:00-04:00,DVAX,neutral
390108.0,"Dynavax Q4 EPS $(0.56) vs $(0.85) Est, Sales $7.3M vs 1.5M Est",2017-03-13 06:03:00-04:00,DVAX,neutral
390109.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-03-08 08:12:00-05:00,DVAX,neutral
390110.0,"Dynavax Says Overall Response Rate for Ongoing Phase 1b/2 Study Investigating SD-101 was 86%, Including 2 Complete Responses, 4 Partial Responses",2017-03-06 08:07:00-05:00,DVAX,neutral
390111.0,20 Biggest Mid-Day Gainers For Wednesday,2017-03-01 12:46:00-05:00,DVAX,neutral
390112.0,Mid-Day Market Update: Dow Rises Over 250 Points; Palo Alto Shares Plunge,2017-03-01 12:17:00-05:00,DVAX,positive
390113.0,Mid-Morning Market Update: Markets Open Higher; Best Buy Sales Miss Views,2017-03-01 10:10:00-05:00,DVAX,positive
390114.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-03-01 08:19:00-05:00,DVAX,neutral
390115.0,"Dynavax Reports FDA Acceptance For Review Of November's HEPSILAV CRL, PDUFA Date Set At August 10th, 2017",2017-02-28 16:05:00-05:00,DVAX,positive
390116.0,25 Stocks Moving In Friday's Pre-Market Session,2017-01-27 08:26:00-05:00,DVAX,neutral
390117.0,Benzinga's Option Alert Recap From January 24,2017-01-24 17:26:00-05:00,DVAX,positive
390118.0,Option Alert: Dynavax Tech Jul 6.0 Calls Sweep: 847 @  ASK  $0.85: 946 traded vs 7049 OI:  Earnings 3/8 Before Open (est)  $4.05 Ref,2017-01-24 14:24:00-05:00,DVAX,positive
390119.0,20 Stocks Moving In Monday's Pre-Market Session,2017-01-23 08:19:00-05:00,DVAX,neutral
390120.0,What Does The Dynavax Restructuring News Mean For Shareholders?,2017-01-05 14:04:00-05:00,DVAX,neutral
390121.0,"Dynavax Shares Resume Trade, Move Lower, Now Down 8%",2017-01-05 13:05:00-05:00,DVAX,neutral
390122.0,Dynavax Shares to Resume Trade at 1:05 p.m. EST,2017-01-05 12:39:00-05:00,DVAX,positive
390123.0,"UPDATE: Dynavax To Incur ~$3M In Estimated Costs; Going Forward, HEPLISAV-B Costs, Prior To Any FDA Decision To Be Less Than $1M/Month",2017-01-05 12:39:00-05:00,DVAX,neutral
390124.0,Dynavax Suspends Manufacturing For HEPLISAV-B and Reduces Workforce By 38%,2017-01-05 12:36:00-05:00,DVAX,neutral
390125.0,Dynavax Shares Halted News Pending,2017-01-05 12:33:00-05:00,DVAX,positive
390126.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-14 08:36:00-05:00,DVAX,neutral
390127.0,"10 Stocks That Rallied Four Days, Then Sold Off Yesterday",2016-12-08 05:15:00-05:00,DVAX,neutral
390128.0,What Is The ASH Conference And Why Should Biotech Investors Care?,2016-12-05 12:16:00-05:00,DVAX,positive
390129.0,"American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4",2016-12-02 10:53:00-05:00,DVAX,neutral
390130.0,"Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%",2016-11-23 10:02:00-05:00,DVAX,neutral
390131.0,Mid-Afternoon Market Update: Corbus Pharmaceuticals Climbs On Positive Resunab Results; Dynavax Shares Slide,2016-11-14 14:23:00-05:00,DVAX,positive
390132.0,12 Biggest Mid-Day Losers For Monday,2016-11-14 12:44:00-05:00,DVAX,negative
390133.0,Mid-Morning Market Update: Crude Oil Down Over 2.5%; Harman Shares Surge Following Samsung Bid,2016-11-14 12:08:00-05:00,DVAX,negative
390134.0,The Technical Take: Dynavax Wrecked After CRL Letter,2016-11-14 11:30:00-05:00,DVAX,neutral
390135.0,Stocks Hitting 52-Week Lows,2016-11-14 10:18:00-05:00,DVAX,negative
390136.0,"JP Morgan Reiterates Neutral Rating On Dynavax, Withdraws Price Target Due To Uncertain Path Forward and Economics Relating To Heplisav",2016-11-14 09:51:00-05:00,DVAX,positive
390137.0,Mid-Morning Market Update: Markets Mostly Higher; Siemens To Acquire Mentor Graphics For $4.5B,2016-11-14 09:48:00-05:00,DVAX,neutral
390138.0,The Market In 5 Minutes: A Couple Of Pharma Stocks Move 70% In Opposite Directions,2016-11-14 09:04:00-05:00,DVAX,neutral
390139.0,Dynavax Shares Plunge 70% Amid Complete Response Letter For Hepatitis B Drug,2016-11-14 08:39:00-05:00,DVAX,positive
390140.0,18 Stocks Moving In Monday's Pre-Market Session,2016-11-14 08:23:00-05:00,DVAX,neutral
390141.0,Dynavax -74% @$3.00 Following Announcement of CRL from FDA,2016-11-14 07:51:00-05:00,DVAX,neutral
390142.0,"Dynavax Q3 EPS $(0.90) vs $(0.75) Est, Revenue $162K vs $2.44M Est",2016-11-07 06:27:00-05:00,DVAX,neutral
390143.0,TheStreet's Adam Feuerstein Tweets on Dynavax: '$DVAX sent invitations to investors for a cancer R&D meeting on Dec. 9 — six days before the Heplisav Hep B vaccine PDUFA date.',2016-10-18 15:18:00-04:00,DVAX,negative
390144.0,Stocks Hitting 52-Week Lows,2016-10-17 10:33:00-04:00,DVAX,negative
390145.0,"Dynavax Presents Early Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, at ESMO 2016",2016-10-09 08:55:00-04:00,DVAX,negative
390146.0,Point72 Capital Reports A 5.6% Stake In Dynavax Technologies,2016-10-06 17:26:00-04:00,DVAX,neutral
390147.0,"Adam Feuerstein @adamfeuerstein Tweet: FDA Precedent Suggests $DVAX Hep B Vaccine Faces High Rejection Risk thestreet.com/story/13840836… When FDA cancels adcomm, drug rejection follows",2016-10-04 10:53:00-04:00,DVAX,negative
390148.0,15 Biggest Mid-Day Gainers For Monday,2016-10-03 12:36:00-04:00,DVAX,neutral
390149.0,Dynavax Shares On The Mend As The Hepsilav Saga Continues,2016-10-03 11:42:00-04:00,DVAX,positive
390150.0,"Dynavax Shares Trading Up ~16%; 8-K Released Earlier Shows Co Received FDA Request For Info On Heplisav-B, Questions In Line With Co's Expectations",2016-10-03 09:59:00-04:00,DVAX,positive
390151.0,18 Stocks Moving In Monday's Pre-Market Session,2016-10-03 08:30:00-04:00,DVAX,neutral
390152.0,13G Filing Shows 5.5% In Dynavax For Glenhill Advisors,2016-09-19 16:17:00-04:00,DVAX,neutral
390153.0,Watch These 7 Huge Call Purchases In Monday Trade,2016-09-19 04:27:00-04:00,DVAX,positive
390154.0,Option Alert: DVAX Nov16 16.0 Calls Sweep: 676 @  ASK  $0.65: 679 traded vs 2500 OI:  Earnings 11/3  $11.81 Ref,2016-09-16 12:14:00-04:00,DVAX,positive
390155.0,Watch These 5 Huge Put Purchases In Tuesday Trade,2016-09-13 02:44:00-04:00,DVAX,positive
390156.0,Option Alert: DVAX Dec16 10.0 Puts: 934 @  ASK  $3.20: 2028 traded vs 4223 OI:  Earnings 11/3  $11.97 Ref,2016-09-12 11:31:00-04:00,DVAX,positive
390157.0,Watch These 5 Huge Put Purchases In Monday Trade,2016-09-12 03:03:00-04:00,DVAX,positive
390158.0,Option Alert: DVAX Jan17 8.0 Puts Sweep: 890 @  ASK  $2.15: 890 traded vs 53 OI: $11.91 Ref,2016-09-09 14:25:00-04:00,DVAX,positive
390159.0,Option Alert: DVAX Jan17 8.0 Puts Sweep: 890 @  ASK  $2.15: 890 traded vs 53 OI: $11.91 Ref,2016-09-09 14:25:00-04:00,DVAX,positive
390160.0,Option Alert: DVAX Fri $10 Puts at the bid: 2000 @ 1.95 vs. Open Interest 255,2016-09-07 11:49:00-04:00,DVAX,positive
390161.0,12 Biggest Mid-Day Gainers For Tuesday,2016-09-06 12:46:00-04:00,DVAX,neutral
390162.0,Benzinga's Volume Movers,2016-09-06 10:45:00-04:00,DVAX,neutral
390163.0,"Must Watch Stocks for September 6, 2016",2016-09-06 05:27:00-04:00,DVAX,neutral
390164.0,Dynavax +14.5% Premarket @$12.50; Co Says PDUFA Date for HEPLISAV-B Still in Effect,2016-09-06 04:45:00-04:00,DVAX,neutral
390165.0,"Dynavax Confirms Cancellation of November 16, 2016 FDA VRBPAC Meeting; Says PDUFA Date of December 15, 2016 for HEPLISAV-B Remains Unchanged",2016-09-06 04:44:00-04:00,DVAX,neutral
390166.0,"Friday's After-Hours Movers: FDA, SEC & Nasdaq Shake Stocks",2016-09-02 17:46:00-04:00,DVAX,negative
390167.0,Technical Alert: Dynavax Tech Crop Attempts To Stablize,2016-09-02 13:37:00-04:00,DVAX,positive
390168.0,The FDA Cancelled Dynavax's Hep-B Drug ADCOM Meeting,2016-09-02 13:18:00-04:00,DVAX,negative
390169.0,UPDATE: FDA To Continue To Evaluate Heplisav And Will Schedule Advisory Committee Meeting In The Future,2016-09-02 12:51:00-04:00,DVAX,neutral
390170.0,"UPDATE: FDA Cancels Nov. 16th ADCOM For Heplisav, BZ NOTE: FDA Notes Meeting Has Been Cancelled To Allow Time To Review Several Outstanding Issues",2016-09-02 12:49:00-04:00,DVAX,positive
390171.0,Dynavax FDA Cancels Nov. 16th Adcom,2016-09-02 12:48:00-04:00,DVAX,negative
390172.0,Dynavax Sells off to Low of $14.54 on Volume,2016-09-02 12:44:00-04:00,DVAX,negative
390173.0,Mid-Day Market Update: Mattress Firm Jumps Following Buyout; Digital Ally Shares Slide,2016-08-08 12:05:00-04:00,DVAX,positive
390174.0,Mid-Morning Market Update: Markets Edge Lower; Tyson Foods Tops Q3 Expectations,2016-08-08 10:08:00-04:00,DVAX,positive
390175.0,Watch These 9 Huge Call Purchases In Tuesday Trade,2016-06-28 01:22:00-04:00,DVAX,positive
390176.0,Option Alert: DVAX Nov16 16.0 Calls Sweep: 694 @  ASK  $2.45: 1452 traded vs 0 OI:  Earnings 8/5  $13.26 Ref,2016-06-27 15:55:00-04:00,DVAX,positive
390177.0,"Dynavax Reports Q1 EPS $(0.70) vs. Est. $(0.63), Rev. $942K vs. Est. $1.1M",2016-05-09 09:01:00-04:00,DVAX,neutral
390178.0,"Cowen & Co Says Heplisav's PDUFA Extension 'Has No Impact On Chances Of Approval, In Our Opinion', Maintains Outperform And $60 PT",2016-04-27 10:43:00-04:00,DVAX,positive
390179.0,"JP Morgan Downgrades Dynavax Technologies to Neutral, Lowers PT to $22.00",2016-04-27 09:23:00-04:00,DVAX,positive
390180.0,Dynavax Downgraded By JP Morgan From Overweight To Neutral,2016-04-27 09:15:00-04:00,DVAX,neutral
390181.0,Dynavax Announces FDA Will Require Additional Time to Review Biologics License Application for HEPLISAV-B,2016-04-27 07:08:00-04:00,DVAX,neutral
390182.0,"Dynavax Presents Encouraging Data From Clinical Trial Of Immuno-Oncology Pdt Candidate, SD-101, Say SD-101 Well Tolerated Across All Dose Cohorts",2016-04-18 16:03:00-04:00,DVAX,positive
390183.0,"Dynavax Shows Encouraging Data From SD-101 Candidate, Showing HEPLISAV-B Provides Higher Protection Against Hep-B Than Engerix",2016-04-18 16:03:00-04:00,DVAX,positive
390184.0,"Dynavax Shares Indicated Higher Following Co. News of FDA Acceptance for Review of BLA, PDUFA Action Date for HEPLISAV-B",2016-03-30 18:48:00-04:00,DVAX,positive
390185.0,"Dynavax Reports Q4 EPS $(0.70) vs. Est. $(0.75), Rev. $685K vs. Est. $1.15M",2016-03-08 07:04:00-05:00,DVAX,neutral
390186.0,"Dynavax, GlaxoSmithKline Battling In Same Industry: Who Will Win?",2016-02-23 12:30:00-05:00,DVAX,positive
390187.0,Option Alert: DVAX Mar16 18.0 Calls Sweep: 600 @  ASK  $2.55: 601 traded vs 2 OI:  Earnings 3/3  $18.54 Ref,2016-02-09 15:06:00-05:00,DVAX,positive
390188.0,Benzinga's Weekend M&A Chatter,2016-01-24 19:32:00-05:00,DVAX,neutral
390189.0,Dynavax Shares Continue To Spike On Celgene Rumor Trading Up 9.25% At $25.03,2016-01-22 11:39:00-05:00,DVAX,positive
390190.0,"Dynavax Shares Spike to High Following Unconfirmed Market Chatter of Potential $45/Share Cash, Stock Bid from Celgene",2016-01-22 11:32:00-05:00,DVAX,positive
390191.0,"Dynavax, AstraZeneca Report Amended Deal for Asthma Drug Candidate",2016-01-19 16:00:00-05:00,DVAX,neutral
390192.0,Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Uniqure Shares Gain Following Release Of Clinical Trial Data,2016-01-07 15:02:00-05:00,DVAX,positive
390193.0,Mid-Day Market Update: Finish Line Drops On Weak Results; Dynavax Shares Spike Higher,2016-01-07 12:03:00-05:00,DVAX,negative
390194.0,Benzinga's Volume Movers,2016-01-07 10:14:00-05:00,DVAX,neutral
390195.0,Mid-Morning Market Update: Markets Open Lower; KB Home Misses Q4 Views,2016-01-07 09:54:00-05:00,DVAX,negative
390196.0,Dynavax +32% Premarket @$28; Both Co-Primary Endpoints Met in Top Line Heplisav-B Phase 3 Results,2016-01-07 08:41:00-05:00,DVAX,positive
390197.0,"Dynavax Reports Top Line Heplisav-B Phase 3 Results, Both Co-Primary Endpoints Met",2016-01-07 07:05:00-05:00,DVAX,positive
390198.0,DVAX Feb16 15.0 Puts: 1499 @  Above Ask!  $1.70: 1501 traded vs 96 OI: $23.33 Ref,2016-01-04 13:43:00-05:00,DVAX,neutral
390199.0,Option Alert: DVAX Jan16 32.0 Calls: 2250 @  ASK  $1.05: 2250 traded vs 624 OI: $23.94 Ref,2015-12-30 13:52:00-05:00,DVAX,positive
390200.0,Option Alert: DVAX Jan16 22.0 Puts Sweep: 2007 @  ASK  $1.49: 2007 traded vs 182 OI: $27.01 Ref,2015-12-28 11:28:00-05:00,DVAX,negative
390201.0,"RBC Capital Initiates Coverage on Dynavax Technologies at Outperform, Announces $48.00 PT",2015-11-30 06:22:00-05:00,DVAX,neutral
390202.0,Filing from Dynavax Shows Registration for Mixed Securities Shelf Offering,2015-11-12 16:35:00-05:00,DVAX,positive
390203.0,"Dynavax Reports Q3 EPS $(0.82) vs $(0.78) Est., Sales $1.2M vs $1.65M Est.",2015-11-05 07:08:00-05:00,DVAX,neutral
390204.0,Dyavax Spikes Higher,2015-10-30 12:29:00-04:00,DVAX,neutral
390205.0,Dynavax Reports Initiation of Immuno-Oncology Clinical Trial of SD-101 in Combo with Merck's KEYTRUDA,2015-10-08 07:01:00-04:00,DVAX,neutral
390206.0,William Blair's Best Ideas In A Volatile Market,2015-08-27 14:36:00-04:00,DVAX,positive
390207.0,"Dynavax Reports Q2 Loss $0.80 Vs Est Loss $1.00, Sales $1.55M Vs Est $1.41M",2015-08-07 16:02:00-04:00,DVAX,negative
390208.0,Benzinga's Volume Movers,2015-07-22 10:33:00-04:00,DVAX,neutral
390209.0,Dynavax Prices 4.545M Offering At $27.50/Share,2015-07-22 08:15:00-04:00,DVAX,neutral
390210.0,Mid-Afternoon Market Update: Dow Dips Over 100 Points; Crude Oil Tumbles 5.5%,2015-07-06 14:52:00-04:00,DVAX,negative
390211.0,Option Alert: Dynavax Jul $$23 Call; 602 Contracts Traded vs $21 OI; Now $21.36,2015-06-11 15:11:00-04:00,DVAX,positive
390212.0,"Merck, Dynavax Partner On Investigating Combination Of Immuno-Oncology Therapies",2015-06-01 08:30:00-04:00,DVAX,neutral
390213.0,ICYMI: Pharmaceutical Stocks Are Moving Big On Monday,2015-03-23 12:13:00-04:00,DVAX,neutral
390214.0,JP Morgan Upgrades Dynavax Technologies To Overweight,2015-03-23 09:23:00-04:00,DVAX,neutral
390215.0,Benzinga's Top Upgrades,2015-03-23 08:33:00-04:00,DVAX,positive
390216.0,"JP Morgan Upgrades Dynavax Technologies to Overweight, Raises PT to $36.00",2015-03-23 04:54:00-04:00,DVAX,neutral
390217.0,"JP Morgan Upgrades Dynavax Technologies to Overweight, Raises PT to $36.00",2015-03-23 04:38:00-04:00,DVAX,neutral
390218.0,"Dynavax Q4 EPS -$0.85 vs -$0.93, Revenue $2.28M vs $2.33M",2015-03-05 06:07:00-05:00,DVAX,neutral
390219.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,DVAX,neutral
390220.0,William Blair's Top BioPharma Stock Picks For Q1 2015,2014-12-26 16:51:00-05:00,DVAX,positive
390221.0,Pharmaceutical Stocks In Play Following Merck/Cubist Deal,2014-12-08 09:09:00-05:00,DVAX,positive
390222.0,"Dynavax, AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma into Phase 2a Clinical Study; AstraZeneca to Fully Fund Trial",2014-12-08 06:06:00-05:00,DVAX,neutral
390223.0,Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of Collaboration With GlaxoSmithKline,2014-11-28 06:05:00-05:00,DVAX,negative
390224.0,Dynavx Technologies effective 10-1 Reverse Spilt Today,2014-11-10 10:08:00-05:00,DVAX,positive
390225.0,Dynavax Technologies Corporation Reports Q3 EPS of $(0.11) vs $(0.09) Est,2014-11-05 06:02:00-05:00,DVAX,neutral
390226.0,How To Quantify The Volatility Of Your Portfolio,2014-10-22 10:03:00-04:00,DVAX,neutral
390227.0,Dynavax Technologies Reports Q2 EPS of $(0.90) vs $(0.06) Est; Revenue of $3.05M vs $2.26M Est,2014-08-07 06:29:00-04:00,DVAX,neutral
390228.0,Dynavax Technologies Corporation Reports Q1 EPS of $(0.05) vs $(0.06) Est; Revenue of $3.50M vs $3.71M Est,2014-05-05 09:01:00-04:00,DVAX,neutral
390229.0,US Stock Futures Edge Higher Ahead Of Earnings,2014-04-15 07:36:00-04:00,DVAX,neutral
390230.0,Dynavax Initiates Phase 3 Study of HEPLISAV-B,2014-04-15 07:12:00-04:00,DVAX,neutral
390231.0,Dynavax Technologies Corporation Reports Q4 EPS of $(0.09) vs $(0.10) Est; Revenue of $2.80M vs $1.92M Est,2014-03-10 16:22:00-04:00,DVAX,neutral
390232.0,"After-Hours Movers Mar. 5, 2014: ERII, PXLW, BIOD, SEED Higher, DVAX, LYV Lower",2014-03-05 18:15:00-05:00,DVAX,negative
390233.0,Dynavax To Receive $5.4 M Milestone Payment,2014-03-03 16:01:00-05:00,DVAX,neutral
390234.0,"UPDATE: Dynavax Cites Timeframe for Response Under MAA Procedure, Expects to Begin Added Clinical Trial",2014-02-18 09:02:00-05:00,DVAX,neutral
390235.0,Dynavax Announces Withdrawal of Heplisav MAA,2014-02-18 09:02:00-05:00,DVAX,neutral
390236.0,Dynavax Submits Responses to EMA Day 120 List of Questions for HEPLISAV MAA,2013-12-19 09:02:00-05:00,DVAX,neutral
390237.0,McNicoll Lewis Vlak Upgrades Dynavax Technologies Corporation to Buy,2013-11-25 08:06:00-05:00,DVAX,neutral
390238.0,Jefferies Reiterates on Dynavax Technologies Awaiting Initiation of HBV-23 Safety Trial,2013-11-08 08:44:00-05:00,DVAX,positive
390239.0,Dynavax Technologies Corporation Reports Q3 EPS of $(0.09) vs $(0.10) Est; Revenue of $2.93M vs $1.83M Est,2013-11-07 17:35:00-05:00,DVAX,neutral
390240.0,Dynavax Prices 76.9M Shares at $1.075/Share for Proceeds $85.5M,2013-10-25 08:34:00-04:00,DVAX,positive
390241.0,UPDATE: Dynavax Expecting HEPLISAV Study Costing $50-55M,2013-10-16 17:12:00-04:00,DVAX,neutral
390242.0,"Dynavax Issues Update on HEPLISAV's Regulatory Path, Will Host Call Tomorrow",2013-10-16 17:10:00-04:00,DVAX,neutral
390243.0,Dynavax Technologies Files Mixed Shelf for Up to $150M,2013-10-07 16:58:00-04:00,DVAX,neutral
390244.0,Form 8-K from Dynavax Technologies Shows VP of Finance Jennifer Lew to Resign,2013-10-01 16:33:00-04:00,DVAX,negative
390245.0,Dynavax Says Phase 3 Data on HEPLISAV for Adults Age 40-70 Published in VACCINE,2013-09-24 16:01:00-04:00,DVAX,neutral
390246.0,Dynavax Technologies Corporation Reports Q2 EPS of $(0.09) vs $(0.10) Est; Revenue of $3.40M vs $2.91M Est,2013-07-29 16:00:00-04:00,DVAX,neutral
390247.0,Dynavax Names Robert Janssen as Chief Medical Officer,2013-07-11 16:02:00-04:00,DVAX,neutral
390248.0,Dynavax Appoints Natale Ricciardi to Its Board of Directors ,2013-07-08 16:00:00-04:00,DVAX,neutral
390249.0,"Brower Piven Encourages Investors Who Have Losses in Excess of $150,000 from Investment in Dynavax Technologies Corporation to Contact Brower Piven Before the August 19, 2013 Lead Plaintiff Deadline ",2013-06-19 16:05:00-04:00,DVAX,positive
390250.0,Stocks Hitting 52-Week Lows,2013-06-14 10:26:00-04:00,DVAX,negative
390251.0,Afternoon Market Losers ,2013-06-13 13:37:00-04:00,DVAX,negative
390252.0,Stocks Hitting 52-Week Lows,2013-06-13 10:23:00-04:00,DVAX,negative
390253.0,UPDATE: Jefferies Lowers PT on Dynavax Technologies Following Major FDA Setback,2013-06-11 11:23:00-04:00,DVAX,negative
390254.0,"Jefferies Maintains Buy on Dynavax Technologies Corporation, Lowers PT to $3.00",2013-06-11 07:42:00-04:00,DVAX,negative
390255.0,"Market Wrap for Monday, June 10: Stocks Little Changed in Quiet Trade ",2013-06-10 16:47:00-04:00,DVAX,neutral
390256.0,Afternoon Market Losers,2013-06-10 14:16:00-04:00,DVAX,negative
390257.0,Morning Market Losers ,2013-06-10 10:09:00-04:00,DVAX,negative
390258.0,"JMP Securities Downgrades Dynavax Technologies Corporation to Market Perform, Removes $2.50 PT",2013-06-10 09:45:00-04:00,DVAX,positive
390259.0,Dynavax Technologies Corporation Reports Q1 EPS of $(0.11) vs $(0.09) Est,2013-05-06 16:12:00-04:00,DVAX,neutral
390260.0,UPDATE: Dynavax Says President Martin Leaving; Sees FDA Meeting in First Half of June,2013-04-30 09:04:00-04:00,DVAX,neutral
390261.0,Dynavax Names Eddie Gray as CEO,2013-04-30 09:01:00-04:00,DVAX,neutral
390262.0,Dynavax Technologies Corporation Reports Q4 EPS of C$(0.11) vs C$(0.08) Est,2013-03-01 16:02:00-05:00,DVAX,neutral
390263.0,"Mid-Afternoon Market Update: Markets Head Down Sharply, Barnes & Noble Remains Up",2013-02-25 16:01:00-05:00,DVAX,positive
390264.0,"Mid-Day Market Update: Markets Turn Red, Dillard's Tumble On Downbeat Results",2013-02-25 12:35:00-05:00,DVAX,neutral
390265.0,Stocks Hitting 52-Week Lows,2013-02-25 10:14:00-05:00,DVAX,negative
390266.0,"Mid-Morning Market Update: Markets Rise At Start, Barnes & Noble's Leonard Riggio To Bid For Retail Assets",2013-02-25 10:08:00-05:00,DVAX,positive
390267.0,UPDATE: MLV & Co. Downgrades Dynavax Technologies to Hold Following Management Meetings,2013-02-25 08:09:00-05:00,DVAX,neutral
390268.0,"McNicoll Lewis Vlak Downgrades Dynavax Technologies Corporation to Hold, Removes $(aN) PT",2013-02-25 07:56:00-05:00,DVAX,neutral
390269.0,Dynavax Shares Plunge Following FDA CRL on Heplisav,2013-02-25 07:55:00-05:00,DVAX,positive
390270.0,Thursday January 10th Watchlist,2013-01-10 16:35:00-05:00,DVAX,neutral
390271.0,Mid-Afternoon Market Update: NuVasive Rises While EXCO Resourced Drops,2013-01-09 15:52:00-05:00,DVAX,neutral
390272.0,"Mid-Day Market Update: Markets Remain Up, Dynavax Continues Rally",2013-01-09 14:19:00-05:00,DVAX,neutral
390273.0,Wednesday January 9th Watchlist,2013-01-09 11:49:00-05:00,DVAX,neutral
390274.0,Benzinga's Top Initiations,2013-01-02 10:02:00-05:00,DVAX,positive
390275.0,UPDATE: J.P. Morgan Initiates Coverage on Dynavax Technologies Corporation with Neutral Rating,2013-01-02 08:41:00-05:00,DVAX,neutral
390276.0,JP Morgan Initiates Coverage on Dynavax Technologies Corporation at Neutral,2013-01-02 07:38:00-05:00,DVAX,positive
390277.0,Benzinga's Top Pre-Market Losers,2012-12-03 08:22:00-05:00,DVAX,negative
390278.0,HealthCor Showing 9.18% Stake in Dynavax,2012-11-21 14:21:00-05:00,DVAX,neutral
390279.0,Mid-Afternoon Market Update: Markets Recovering; Penn National Gaming Still Up,2012-11-16 16:04:00-05:00,DVAX,neutral
390280.0,Mid-Day Markets Update: Markets Recover on Fiscal Cliff Meeting; Casino Stocks Continue to Ramp,2012-11-16 13:10:00-05:00,DVAX,neutral
390281.0,"UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Dynavax Technologies Corporation",2012-11-16 12:22:00-05:00,DVAX,negative
390282.0,Mid-Morning Market Update: Markets Down; Casino Equities Get a Boost,2012-11-16 10:36:00-05:00,DVAX,positive
390283.0,"Jefferies & Company Maintains Dynavax Technologiesoration at Buy, Lowers PT from $6 to $5",2012-11-16 07:37:00-05:00,DVAX,negative
390284.0,"McNicoll Lewis Vlak Maintains Dynavax Technologiesoration at Buy, Lowers PT from $10 to $7.50",2012-11-16 06:56:00-05:00,DVAX,negative
390285.0,Dynavax Shares Down 57%,2012-11-15 16:30:00-05:00,DVAX,positive
390286.0,Dynavax Resumes Trading,2012-11-15 16:30:00-05:00,DVAX,neutral
390287.0,Dynavax Shares to Resume at 4:30PM ET,2012-11-15 16:16:00-05:00,DVAX,positive
390288.0,PREVIEW: Dynavax to Resume Trading at 4:30pm,2012-11-15 16:12:00-05:00,DVAX,neutral
390289.0,Dynavax Fails to Win FDA Panel Backing for Hepatitis B Vaccine,2012-11-15 13:57:00-05:00,DVAX,positive
390290.0,"FDA Panel Says Dynavax's HEPLISAV Hasn't Shown Safety, Vote 5-8 With One Abstain",2012-11-15 13:43:00-05:00,DVAX,negative
390291.0,FDA Panel Votes 13-1 Dynavax's HEPLISAV Effective,2012-11-15 13:23:00-05:00,DVAX,positive
390292.0,Mid-Afternoon Market Update: Markets Go Red; AK Steel Plunges Again,2012-11-13 15:29:00-05:00,DVAX,neutral
390293.0,UPDATE: FDA Says Dynavax's HEPLISAV Does Not Have Any Clinically Significant Differences in Safety vs Glaxo's Engerix-B,2012-11-13 12:42:00-05:00,DVAX,positive
390294.0,UPDATE: FDA Briefing Document for Nov. 15th Panel Meeting on Dynavax's HEPLISAV,2012-11-13 12:33:00-05:00,DVAX,neutral
390295.0,"On November 15, 2012 FDA Committee will Meet to Discuss and Make Recommendations on Hepatitis B Vaccine Manufactured by Dynavax",2012-11-13 12:26:00-05:00,DVAX,neutral
390296.0,FDA Issues Staff Review on Dynavax's Heplisav Hep B Vaccine,2012-11-13 12:23:00-05:00,DVAX,neutral
390297.0,Dynavax Spikes Higher,2012-11-13 12:22:00-05:00,DVAX,neutral
390298.0,"JMP Securities Initiated Coverage on Dynavax Technologiesoration at Market Outperform, Announced PT to $6",2012-11-06 09:55:00-05:00,DVAX,positive
390299.0,Benzinga's Top Initiations,2012-11-06 07:37:00-05:00,DVAX,positive
390300.0,Dynavax Technologiesoration Reports Q3 EPS $-0.10 vs $-0.08 Est,2012-11-01 09:01:00-04:00,DVAX,neutral
390301.0,Dynavax to Initiate Phase 1 Studies For TLR-9 Agonist For Asthma ,2012-10-31 09:02:00-04:00,DVAX,neutral
390302.0,Benzinga Mid-Morning Market Update,2012-10-16 10:37:00-04:00,DVAX,neutral
390303.0,"Five trading ideas for Tuesday, Aug 28",2012-08-28 13:00:00-04:00,DVAX,neutral
390304.0,Dynavax Announces FDA Advisory Committee to Review HEPLISAV Dynavax Announces FDA Advisory Committee to Review HEPLISAV,2012-08-28 09:02:00-04:00,DVAX,neutral
390305.0,Dynavax Tech Names Larson CFO,2012-08-13 16:01:00-04:00,DVAX,neutral
390306.0,"Jefferies & Company Maintains Dynavax Technologiesoration at Buy, Raises PT from $5 to $6",2012-08-02 06:33:00-04:00,DVAX,neutral
390307.0,Dynavax Submits HEPLISAV(TM) for EU Marketing Authorization  ,2012-07-24 09:01:00-04:00,DVAX,neutral
390308.0,Dynavax Announces FDA Acceptance of HEPLISAV BLA  ,2012-06-26 09:01:00-04:00,DVAX,positive
390309.0,UPDATE: Jefferies Lowers PT to $5 on Dynavax Technologies; Commercial Concerns  ,2012-05-10 08:26:00-04:00,DVAX,negative
390310.0,"Jefferies & Company Maintains Dynavax Technologiesoration at Buy, Lowers PT from $6 to $5",2012-05-10 06:34:00-04:00,DVAX,negative
390311.0,Dynavax Prices Public Offering of Common Stock; 17.5M Shares at $4.25/Share,2012-05-09 08:50:00-04:00,DVAX,positive
390312.0,Dynavax Embarks on Transition to Commercialization  ,2012-05-08 16:03:00-04:00,DVAX,neutral
390314.0,Dynavax Reports Q1 EPS of $(0.11) vs $(0.10); Revenues $2.4M vs $5.75M Est ,2012-04-27 16:03:00-04:00,DVAX,neutral
390315.0,Dynavax Reports HEPLISAV BLA Submission  ,2012-04-26 16:00:00-04:00,DVAX,neutral
390316.0,Dynavax Reports Final Phase 3 Data for HEPLISAV in CKD Patients and New Data From Booster Trial in Hemodialysis Patients; Superiority Endpoint Had Been Met in Trial  ,2012-03-27 09:01:00-04:00,DVAX,positive
390317.0,Dynavax Reports Q4 EPS $(0.03) vs $(0.07) Est; Revs $11.4M May Not Compare vs $5.77M Est,2012-03-06 08:05:00-05:00,DVAX,neutral
390318.0,Weekly Traders Homework: Oil Is The Hot Theme (w/ Economic Calendar and Stock Radar),2012-02-27 00:26:00-05:00,DVAX,neutral
390319.0,Weekly Traders Homework: Contrarian Indicators Flashing (w/ Economic Calendar and Stock Radar),2012-02-20 23:47:00-05:00,DVAX,neutral
390320.0,Phase 3 Data on HEPLISAV in Adults Aged 18-55 Published in VACCINE  ,2012-02-13 09:01:00-05:00,DVAX,neutral
390321.0,Weekly Traders Homework: The First Sign Of Weakness In 2012,2012-02-12 22:52:00-05:00,DVAX,negative
390322.0,Dynavax Technologiesoration Hits 52-Week High of $4.39,2012-02-06 11:58:00-05:00,DVAX,neutral
390323.0,Dynavax Technologiesoration Hits 52-Week High of $4.26,2012-02-03 09:33:00-05:00,DVAX,neutral
390324.0,Dynavax Technologiesoration Hits 52-Week High of $3.84,2012-02-02 09:32:00-05:00,DVAX,neutral
390325.0,Dynavax Reports on Heplisav(TM) Pre-BLA Meeting With FDA  ,2012-02-02 09:01:00-05:00,DVAX,neutral
390326.0,Dynavax Technologiesoration Hits 52-Week High of $3.69,2012-01-12 11:16:00-05:00,DVAX,neutral
390327.0,Dynavax Technologiesoration Hits 52-Week High of $3.63,2012-01-11 10:31:00-05:00,DVAX,neutral
390328.0,Dynavax Technologiesoration Hits 52-Week High of $3.59,2012-01-09 15:31:00-05:00,DVAX,neutral
390329.0,JPMorgan Confab Kicks Off Biotech 2012,2012-01-05 11:46:00-05:00,DVAX,neutral
390330.0,Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist for Asthma,2011-12-21 09:00:00-05:00,DVAX,positive
390331.0,Dynavax Initiates Proof of Mechanism Trial in Lupus Patients  ,2011-12-20 09:06:00-05:00,DVAX,neutral
390332.0,Dynavax Announces Exercise in Full of Overallotment Option and Completion of Public Offering of Common Stock  ,2011-11-08 16:00:00-05:00,DVAX,neutral
390333.0,Dynavax Prices Public Offering of 24M Shares at $2.50,2011-11-03 08:22:00-04:00,DVAX,positive
390334.0,Dynavax Announces Proposed Public Offering of Common Stock; No Amount Given  ,2011-11-02 16:00:00-04:00,DVAX,negative
390335.0,Dynavax Confirms HEPLISAV Submission Strategies With U.S. FDA and EMA  ,2011-10-27 16:10:00-04:00,DVAX,neutral
390336.0,Dynavax Phase 3 Data in Chronic Kidney Disease Demonstrates Superiority of HEPLISAV vs Engerix-B,2011-10-27 07:11:00-04:00,DVAX,positive
390337.0,Notable Call Options Activity in Dynavax Technologies,2011-10-26 11:19:00-04:00,DVAX,neutral
390338.0,Dynavax and GlaxoSmithKline Expand Their Worldwide Strategic Alliance  ,2011-10-21 09:02:00-04:00,DVAX,positive
390339.0,Dynavax Reports Positive Immunogenicity Data From an Analysis of Hypo-Responsive Populations in HEPLISAV(TM) Phase 3 Trial  ,2011-10-10 09:00:00-04:00,DVAX,positive
390340.0,Dynavax Reports Diabetic Subset Data From Modified Intent to Treat Analysis of the HEPLISAV Phase 3 Trial,2011-10-06 16:31:00-04:00,DVAX,positive
390341.0,Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic,2011-10-05 09:00:00-04:00,DVAX,neutral
390342.0,Dynavax Reports Modified Intent to Treat Analysis From the HEPLISAV Phase 3 Trial,2011-10-03 09:07:00-04:00,DVAX,positive
390343.0,Dynavax Reports Modified Intent to Treat Analysis From the HEPLISAV(TM) Phase 3 Trial in Healthy Adults Over Age 40  ,2011-10-03 09:02:00-04:00,DVAX,positive
390344.0,Dynavax Reports Complete Results From the HEPLISAV Phase 3 Trial,2011-09-18 16:14:00-04:00,DVAX,neutral
390345.0,Notable Call Options Activity in Dynavax Technologies,2011-09-13 15:38:00-04:00,DVAX,neutral
390346.0,"NASDAQ's Top Gainers for Monday: PAETEC, Sify Technologies, Dynavax, Limelight Networks",2011-08-02 11:06:00-04:00,DVAX,positive
390347.0,Hearing Positive Chatter on Dynavax Tech Due to Upcoming Meeting with Goldman Sachs,2011-08-01 15:47:00-04:00,DVAX,positive
390348.0,"NASDAQ Top Percentage Gainers: Town Sports International, AXT, Dynavax, Green Mountain Coffee Roasters",2011-07-29 12:28:00-04:00,DVAX,positive
390349.0,Options Brief: Dynavax Technologies,2011-07-28 10:10:00-04:00,DVAX,neutral
390350.0,FDA Agrees with Dynavax on Consistency of HEPLISAV Lots,2011-07-28 08:14:00-04:00,DVAX,positive
390351.0,Morning Market Losers ,2011-07-20 10:07:00-04:00,DVAX,negative
390352.0,Dynavax Phase 3 Demonstrates Superiority and Safety of HEPLISAV vs. Engerix-B,2011-07-20 08:03:00-04:00,DVAX,positive
390353.0,Dynavax Reports Q2 EPS of $(0.09) vs. $(0.11) Est; Revenues $7.27M vs. $6.13M Est,2011-07-20 07:35:00-04:00,DVAX,neutral
390354.0,Jefferies Reports Favorable ACIP Stance For Dynavax Tech,2011-06-24 08:50:00-04:00,DVAX,positive
390355.0,Top Percentage Gainers and Losers as of 12pm 6/23/11,2011-06-23 12:03:00-04:00,DVAX,negative
390356.0,Jefferies Maintains Buy on Dynavax Technologies,2011-06-09 07:37:00-04:00,DVAX,neutral
390357.0,Dynavax Technologies Spiking Higher on Heavy Volume ,2011-06-07 11:50:00-04:00,DVAX,neutral
390358.0,Dynavax Completes Phase 3 Study of HEPLISAV,2011-05-25 16:31:00-04:00,DVAX,neutral
390359.0,Dynavax Initiates First Human Trial in Lupus Program  ,2011-04-20 12:31:00-04:00,DVAX,neutral
390360.0,Wedbush Initiates Coverage On Dynavax With Outperform Rating,2011-03-25 07:45:00-04:00,DVAX,neutral
390361.0,Dynavax Reports Q4 Loss of $0.14 per share,2011-03-08 09:17:00-05:00,DVAX,neutral
390362.0,Data from Dynavax for HBV Candidate - Analyst Blog,2010-12-27 13:03:00-05:00,DVAX,neutral
390363.0,Data from Dynavax for HBV Candidate - Analyst Blog,2010-12-27 12:30:00-05:00,DVAX,neutral
390364.0,Jefferies & Company Initiates Coverage on Dynavax Technologies,2010-11-08 11:38:00-05:00,DVAX,neutral
390365.0,Jefferies Initiates Buy Rating on Dynavax Technologies,2010-11-08 10:40:00-05:00,DVAX,neutral
390366.0,Dynavax Pops on Stock Purchase Agreement (DVAX),2010-09-20 17:05:00-04:00,DVAX,positive
390367.0,Dynavax Announces $30 Million Common Stock Purchase (DVAX),2010-09-20 16:50:00-04:00,DVAX,neutral
390368.0,Oppenheimer's Current Biotech Ratings,2010-09-13 10:41:00-04:00,DVAX,neutral
390369.0,Dynavax (DVAX) Upgraded To Outperform,2010-05-13 14:04:00-04:00,DVAX,neutral
390370.0,"Benzinga’s Top Upgrades (MS, TDC, HAL, DVAX, SUPX)",2010-05-13 10:31:00-04:00,DVAX,positive
390371.0,"Market Round-up (GNW, NLX-U, DVAX, BKS, BGP)",2010-01-26 14:02:00-05:00,DVAX,neutral
390372.0,"Benzinga’s Biggest Losers (SIGA, CIEN, FCEL, DVAX, RMIX)",2009-12-10 12:07:00-05:00,DVAX,negative
390373.0,"Top Gainers of the Day (XRTX, MNDO, DVAX)",2009-09-10 22:25:00-04:00,DVAX,positive
390374.0,Dynavax makes 52- Week high after FDA Removes Clinical Hold on HEPLISAVTM Phase 3 Hepatitis B Vaccine,2009-09-10 11:14:00-04:00,DVAX,neutral
